Etanercept: an overview of dermatologic adverse events.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 21242398)

Published in Arch Dermatol on January 01, 2011

Authors

Lidian L A Lecluse1, Emmilia A Dowlatshahi, C E Jacqueline M Limpens, Menno A de Rie, Jan D Bos, Phyllis I Spuls

Author Affiliations

1: Department of Dermatology, Academic Medical Center, University of Amsterdam, the Netherlands. l.l.lecluse@amc.uva.nl

Articles by these authors

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol (2007) 1.06

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges (2011) 1.04

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

Overview of psoriasis. Dermatol Ther (2004) 1.04

Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. J Clin Immunol (2004) 1.00

Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol (2013) 0.99

Interventions for nail psoriasis. Cochrane Database Syst Rev (2013) 0.97

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95

Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol (2011) 0.94

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol (2015) 0.92

Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91

Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.90

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89

Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res (2009) 0.89

T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89

The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87

The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86

Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86

Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85

Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83

Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol (2007) 0.83

Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med (2010) 0.82

Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol (2008) 0.82

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82

Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat (2011) 0.82

Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol (2008) 0.82

Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res (2004) 0.82

Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis (2013) 0.82

Topical treatments in psoriasis: today and tomorrow. Clin Dermatol (2008) 0.82

Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol (2006) 0.82

Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol (2005) 0.81

Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol (2003) 0.81

Accuracy and reliability of teledermatoscopy with images taken by general practitioners during everyday practice. J Telemed Telecare (2013) 0.81

In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol (2004) 0.80

Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol (2002) 0.80

Tertiary teledermatology: a systematic review. Telemed J E Health (2010) 0.80

Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.79

Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. Arch Dermatol Res (2012) 0.79

Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol (2009) 0.79

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79

Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol (2004) 0.79

The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol (2009) 0.78

Measurement properties of outcome measures for vitiligo. A systematic review. Arch Dermatol (2012) 0.78

Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol (2010) 0.78

Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. Acta Derm Venereol (2016) 0.78

Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol (2008) 0.77

Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol (2006) 0.77

Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol (2004) 0.77

Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol (2004) 0.77

Prospective comparison of three guideline development methods for treatment of actinic keratosis. BMJ Qual Saf (2011) 0.77

UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. Photochem Photobiol (2002) 0.77

Atopic eczema or atopiform dermatitis. Exp Dermatol (2010) 0.76